Most of the current tumor-targeted antibodies only serve a subset of patients and a subset of cancers. Many of them also unintentionally target healthy tissues, causing severe side effects.

We aim to become the leading provider of truly tumor-specific monoclonal antibody (mAb) based therapies for all patients, for all cancer types, without targeting healthy cells.

Sugars (glycans) play a crucial role in modifying many essential proteins in our bodies, including those found on the surfaces of cancer cells. In most cancers, these sugar structures are shortened compared to healthy cells, offering a unique opportunity to differentiate between cancerous and normal cells.

Combotope Therapeutics has developed SMART-Phage, a proprietary mAb discovery platform designed to target cancer cells without impacting healthy cells. SMART-Phage combines glycan and peptide-focused scFv technology, providing antibodies that specifically target the tumor form of a particular protein on cancer cells while leaving healthy cells expressing the same, but correctly glycosylated protein, untouched. Our scFv sequences are of high affinity, making them suitable for easy integration into numerous therapeutic modalities for effective cancer treatment.

Our business model involves identifying, developing, and licensing proprietary scFv sequences that specifically target cancer proteins with aberrant O-glycosylation.

Through strategic partnerships, we will accelerate the development and commercialization of pioneering scFv-based off-the-shelf and personalized anti-cancer therapies.

Combotope Therapeutics ApS

Org chart

Teams

Offices